Breaking News

Roche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B Deal

Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins.

Roche has entered a definitive merger agreement to acquire 89bio for a total equity value of approximately $2.4 billion. Stockholders would also receive a contingent value right (CVR), representing a total deal value of up to approximately $3.5 billion. 89bio is a clinical-stage biopharma company pioneering therapies for the treatment of liver and cardiometabolic diseases. Pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients as w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters